From the publishers of JADPRO

MPN Resource Center

Advertisement
Advertisement
FROM THE EDITOR

Welcome to the JADPRO MPN Resource Center! We’ve expanded our previous platform to provide you more information, education, and cutting-edge research from the field of myeloproliferative neoplasms. We’re excited to provide this expanded offering to you and your colleagues. Take a look around, and send us your feedback to editor@advancedpractitioner.com

Lindsey Lyle, MS, PA-C, Senior Instructor, Blood Cancers and Bone Marrow Transplant Program, University of Colorado, Anschutz Medical Campus

News & Literature Highlights

2021 American Society of Hematology Annual Meeting Abstract

Final results of a phase 2 study of sotatercept (ACE-011) for anemia of MPN-associated myelofibrosis

2021 American Society of Hematology Annual Meeting Abstract

A phase 2 study of pemigatinib (FIGHT-203; INCB054828) in patients with myeloid/lymphoid neoplasms (MLNs) with fibroblast growth factor receptor 1 (FGFR1) rearrangement (MLNFGFR1)

2021 American Society of Hematology Annual Meeting Abstract

Disease-modifying potential of BET inhibitor pelabresib (CPI-0610) as demonstrated by improvements in bone marrow function and clinical activity in patients with myelofibrosis – preliminary data

2021 American Society of Hematology Annual Meeting Abstract

Safety and tolerability of fedratinib (FEDR), an oral inhibitor of janus kinase 2 (JAK2), in patients with intermediate- or high-risk myelofibrosis (MF) previously treated with ruxolitinib (RUX): results from the phase 3b FREEDOM trial

2021 American Society of Hematology Annual Meeting Abstract

Rusfertide (PTG-300) induction therapy rapidly achieves hematocrit control in polycythemia vera patients without the need for therapeutic phlebotomy

Annals of Hematology

Ruxolitinib-treated polycythemia vera patients and their risk of secondary malignancies

CancerNetwork

FDA Approves Ropeginterferon Alpha-2b for Polycythemia Vera

European Journal of Haematology

Bleeding complications in bcr-abl-negative myeloproliferative neoplasms (MPN): A retrospective single-center study of 829 MPN patients

Cancers

Recent advances in molecular diagnostics and targeted therapy of myeloproliferative neoplasms

Current Hematologic Malignancy Reports

Philadelphia-negative myeloproliferative neoplasms around the COVID-19 pandemic

Advertisement
Advertisement